Synageva BioPharma Corp Garners $30,000,000 Series F Financing Round

  • Feed Type
  • Date
  • Company Name
    Synageva BioPharma Corp
  • Mailing Address
    60 Hickory Drive Waltham, MA 02451
  • Company Description
    Synageva BioPharma’s ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva’s proprietary platform technologies, including SEPTM, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Our platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series F
  • Proceeds Purposes
    This funding will be utilized to advance Synageva’s products to later stages of development in order to maximize their value for partnership discussions.
  • M&A Terms
  • Venture Investor
    Baker Brothers Investments
  • Venture Investor
    Tullis-Dickerson & Co., Inc.
  • Venture Investor

Trending on Xconomy